Abstract:BACKGROUND: Optimal iron levels in patients on hemodialysis are currently unknown, and a higher level than that for the healthy population is usually set for such patients considering the use of erythropoiesis-stimulating agents or the occurrence of chronic inflammation. However, excessive iron causes oxidative stress and impairment of its utilization by cells. Therefore we investigated the relationship between hemoglobin (Hb) level and iron status in hemodialysis patients to identify the optimal iron levels for patients undergoing hemodialysis.METHODS: A total of 208 outpatients on maintenance hemodialysis were followed up between July 2006 and June 2007. Men accounted for 64.9% cases [mean age, 59.3 ± 13.1 years and median dialysis history, 7.7 (3.6-13.2) years], and diabetic nephropathy accounted for 25.0% cases. Hemoglobin level was measured twice a month and serum ferritin, serum iron, and total iron-binding capacity were measured once a month. The doses of recombinant human erythropoietin and low-dose iron supplement were adjusted to maintain a hemoglobin level of 10-11 g/dL, according to the guidelines of the Japanese Society for Dialysis Therapy. Hepcidin was measured at baseline. Using the mean values for 1-year period, the relationships among hemoglobin, serum ferritin levels, and transferrin saturation levels were investigated based on a receiver operating characteristic curve and a logistic regression model. In addition, the correlations among serum ferritin, transferrin saturation, and hepcidin levels were analyzed by Pearson product-moment correlation coefficient and linear regression model.RESULTS: By receiver operating characteristic curve, the cutoff point of serum ferritin and transferrin saturation levels with a hemoglobin ≥10 g/dL showed <90 ng/mL (sensitivity: 69.1%, specificity: 72.1%, p < 0.001) and ≥20% (sensitivity: 77.6%, specificity: 48.8%, p = 0.302). Upon logistic regression model analysis with a hemoglobin ≥10 g/dL as the endpoint, the analysis of odds ratios relative to a group with serum ferritin ≥90 ng/mL and transferrin saturation <20% revealed that the group with serum ferritin <90 ng/mL and transferrin saturation ≥20% had the highest ratio: 46.75 (95% confidence interval: 10.89-200.70, p < 0.001). In Pearson product-moment correlation coefficient, hepcidin showed a strong positive correlation with serum ferritin [r = 0.78 (95% confidence interval: 0.72-0.83, p < 0.001)] and a weak positive correlation with transferrin saturation [r = 0.18 (95% confidence interval: 0.04-0.31, p = 0.010)]. In the multivariable analyses of the linear regression model, a positive relationship was shown between hepcidin and serum ferritin [β-coefficient of 0.30 (95% confidence interval: 0.27-0.34, p < 0.001)]; however, no relationship was shown with transferrin saturation [β-coefficient of 0.09 (95% confidence interval: -0.31-0.49, p = 0.660)].CONCLUSIONS: In this study, the iron status of serum ferritin <90 ng/mL and transferrin saturation ≥20% was optimal in hemodialysis patients receiving recombinant human erythropoietin for anemia therapy. This result indicates that the threshold values for the optimal iron status may be lower than those currently recommended in iron-level management guideline.

Growth differentiation factor GDF-15 does not influence iron metabolism in stable chronic haemodialysis patients

GDF-15 and hepcidin as a therapeutic target for anemia in chronic kidney disease

Enzymatically driven transport: a kinetic theory for nuclear export.

7-aminoclonazepam is superior to clonazepam for detection of clonazepam use in oral fluid by LC-MS/MS.

Elevated circulating growth differentiation factor 15 is related to decreased heart rate variability in chronic kidney disease patients

On criticising Israel. Response from author of original paper. Comparison of the number of Palestinians killed by the Israeli Defence Force (IDF) with those killed in 9/11.

High intact fibroblast growth factor 23 levels associated with low hemoglobin levels in patients on chronic hemodialysis

Growth differentiation factor-15 in young sickle cell disease patients: relation to hemolysis, iron overload and vascular complications

Growth Differentiation Factor-15 and Incident Chronic Kidney Disease: a Population-Based Cohort Study.

Growth differentiation factor–15 predicts the prognoses of patients with acute coronary syndrome: a meta-analysis

Low levels of serum ferritin and moderate transferrin saturation lead to adequate hemoglobin levels in hemodialysis patients, retrospective observational study

Association between Serum GDF-15 and Cognitive Dysfunction in Hemodialysis Patients

Growth differentiation factor 15 is a promising diagnostic and prognostic biomarker in colorectal cancer

The correlation between serum growth differentiation factor 15 and malnutrition in patients with end-stage kidney disease on hemodialysis

Giant cell tumor of the spine: A review of 9 surgical interventions in 6 cases

The association between growth differentiation factor-15, erythroferrone, and iron status in thalassemic patients

Role and Mechanism of Growth Differentiation Factor 15 in Chronic Kidney Disease

Iron Indices Mediate but Not Modify Association of Parathyroid Hormone with Erythropoietin Resistance in Hemodialysis Patients

Fibroblast growth-factor 23 and vitamin D are associated with iron deficiency and anemia in children with chronic kidney disease

Fungal endophthalmitis: a report of two cases.

Serum Hepcidin in Haemodialysis Patients: Associations with Iron Status and Microinflammation.